Assembly Biosciences to Present Positive Phase 1a Data for ABI-6250 at AASLD Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 /CourierPR/ -- Assembly Biosciences, a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, will present positive Phase 1a safety, tolerability, and target engagement data for its ABI-6250 program at The Liver Meeting® 2026. The event, organized by the American Association for the Study of Liver Diseases (AASLD), is scheduled for November 5-9, 2026, in Denver, Colorado.

According to Dr. Anuj Gaggar, the chief medical officer of Assembly Biosciences, the Phase 1a findings support the safety profile of ABI-6250 and demonstrate potent target engagement.

The presentations will include safety, tolerability, and pharmacodynamic findings from the randomized, blinded Phase 1a study of ABI-6250 in healthy participants. ABI-6250, an oral small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP), was well tolerated at the doses evaluated, with no serious adverse events reported. The study demonstrated dose-dependent, reversible increases in total and conjugated bile acids, consistent with NTCP target engagement.

The posters will be presented by Dr. Edward J. Gane from the University of Auckland. MT.

The press release also notes that the information in this document contains forward-looking statements that are subject to certain risks and uncertainties. These risks and uncertainties include the potential for ABI-6250 to advance into Phase 2 studies and the company's ability to secure additional funding and maintain financial resources.

The release further states that ABI-6250 is an investigational oral small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP), a membrane protein selectively expressed on hepatocytes that facilitates bile acid transport into cells and also serves as the receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV) to enter hepatocytes. Assembly Bio is developing ABI-6250 for the treatment of chronic HDV infection, where the targeting of NTCP blocks viral infection and is a clinically validated mechanism. ABI-6250 is also being evaluated in cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), where bile acid accumulation in the liver drives liver inflammation and liver injury. The targeting of NTCP by ABI-6250 blocks the uptake of bile acids into liver cells.

Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases, and hepatitis B virus (HBV).